All In Biotech

Drug Trial Radar · NCT05381948

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Last checked: Nov 20, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Jun 30, 2022

Primary completion

Nov 29, 2023

Study completion Apr 24, 2024

Sponsor

Lead sponsor
EyePoint Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.

Conditions

  • Wet Age-related Macular Degeneration

Interventions

  • EYP-1901Drug

    Intravitreal Injection

  • Aflibercept 2mg/0.05mL Inj,OphDrug

    Intravitreal Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32Time frame: Baseline (Day 1) and Weeks 28 and 32

Locations

67 sites in 1 country. Site status is shown where the registry gives one.

  • EyePoint Investigative Site

    Phoenix, Arizona

  • EyePoint Investigative Site

    Springdale, Arkansas

  • EyePoint Investigative Site

    Beverly Hills, California

  • EyePoint Investigative Site

    Campbell, California

  • EyePoint Investigative Site

    Encino, California

  • EyePoint Investigative Site

    Fullerton, California

  • EyePoint Investigative Site

    Glendale, California

  • EyePoint Investigative Site

    Huntington Beach, California

  • EyePoint Investigative Site

    Irvine, California

  • EyePoint Investigative Site

    Pasadena, California

  • EyePoint Investigative Site

    Poway, California

  • EyePoint Investigative Site

    Redlands, California

  • EyePoint Investigative Site

    Sacramento, California

  • EyePoint Investigative Site

    Walnut Creek, California

  • EyePoint Investigative Site

    Lakewood, Colorado

  • EyePoint Investigative Site

    Clearwater, Florida

  • EyePoint Investigative Site

    Coral Springs, Florida

  • EyePoint Investigative Site

    Lakeland, Florida

  • EyePoint Investigative Site

    Melbourne, Florida

  • EyePoint Investigative Site

    Miami, Florida

  • EyePoint Investigative Site

    Pensacola, Florida

  • EyePoint Investigative Site

    Sarasota, Florida

  • EyePoint Investigative Site

    St. Petersburg, Florida

  • EyePoint Investigative Site

    Tampa, Florida

  • EyePoint Investigative Site

    Winter Haven, Florida

  • EyePoint Investigative Site

    Marietta, Georgia

  • EyePoint Investigative Site

    ‘Aiea, Hawaii

  • EyePoint Investigative Site

    Chicago, Illinois

  • EyePoint Investigative Site

    Lemont, Illinois

  • EyePoint Investigative Site

    Carmel, Indiana

  • EyePoint Investigative Site

    West Des Moines, Iowa

  • EyePoint Investigative Site

    Baltimore, Maryland

  • EyePoint Investigative Site

    Hagerstown, Maryland

  • EyePoint Investigative Site

    Owings Mills, Maryland

  • EyePoint Investigative Site

    Boston, Massachusetts

  • EyePoint Investigative Site

    Springfield, Massachusetts

  • EyePoint Investigative Site

    Grand Rapids, Michigan

  • EyePoint Investigative Site

    Saint Louis, Michigan

  • EyePoint Investigative Site

    St Louis, Missouri

  • EyePoint Investigative Site

    Reno, Nevada

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.